Kornimate/medical-research-clean huggingface dataset:
mymenoplan: online resource for improving women's menopause knowledge and informed decision-making

Conditions: Menopause; Premenopause; Postmenopause

Summary: as part of a national institute on aging -funded r01, the investigators developed an evidence-based, multi-media digital resource entitled mymenoplan to help women learn about the menopause transition, and the symptoms and treatments of perimenopause/menopause. mymenoplan is also designed to help women learn about the effectiveness of treatments for a comprehensive list of midlife symptoms and compare treatments that may help with the specific symptoms women are experiencing.

the purpose of this research study is to: 1. investigate how women randomly assigned to visit mymenoplan use the website (time spent on website, treatment and symptom page views, use of interactive tools, and use of the mymenoplan tool). 2. compare the ratings of women randomly assigned to mymenoplan to those randomly assigned to other menopause websites for perceived quality of information, readability, self-efficacy, and credibility of these online menopause resources.

Eligibility criteria:
inclusion criteria: * as stated above exclusion criteria: * n/a

Keywords: computer-assisted decision making internet-based intervention
mri targeted focal laser thermal therapy of prostate cancer followed by radical prostatectomy

Conditions: Prostate Neoplasm

Summary: this is a clinical research study designed to measure the effectiveness of focal interstitial laser thermal therapy (iltt) at killing prostate tumours. patients with "low risk" prostate cancer (trans rectal us guided biopsy positive) will undergo an mri scan to try to localize the tumour. if the mri detects the tumour they will then undergo a perineal ablative procedure (iltt) under general anaesthetic. seven days following iltt they will come back to the hospital for a radical retoropubic prostatectomy (rrp) procedure, which is the removal of a prostate gland through a surgical incision. after removal, the prostate will undergo further analysis to determine the exact location of cancer and evaluate the extent of cancer death caused by iltt.


Eligibility criteria:
inclusion criteria: * men 40-80 years of age; * histologically-proven prostate carcinoma; * prostate cancer clinical stage t1c and t2a * prostate mri must confirm area suspicious for cancer in the sector of the positive biopsy; * a minimum of six (6) weeks between the prostate biopsy and the inclusion visit; * prostate specific antigen (psa) level 15 ng/ml exclusion criteria: * medically unfit for radical retropubic prostectomy (rrp) surgery * patients who are unwilling or unable to give informed consent; * patients with foci location in the apex of the prostate or isolated transition zone cancers * patients who have received androgen suppression therapy * patients who have received or are receiving chemotherapy for prostate carcinoma; * patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive including hifu, tuna, rita, microwave, turp, cryotherapy or any curative treatment * patients who have undergone radiation therapy for prostate cancer or to the pelvis * any condition, or history of illness or surgery that, in the opinion of the investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies); * patients with a history of non compliance with medical therapy and/or medical recommendations;

Keywords: prostate neoplasm localized photothermal radical prostatectomy
immunogenicity and safety of the hepatitis b vaccine hepavax-gene tf and a comparator hepatitis b vaccine in newborns

Conditions: Hepatitis B

Summary: the primary purpose of this study is to determine whether hepavaxgene tf is non-inferior to the comparator vaccine both at impeding hepatitis b transmission from mothers positive for chronic hepatitis b (stratum 1) to their children and also in terms of seroconversion rate in children of mothers negative for chronic hepatitis b (stratum 2) one month after completion of the immunization schedule.


Eligibility criteria:
three types of subject: neonates whose mothers are positive for both hbsag and hbeag neonates whose mothers are positive for only hbsag neonates whose mothers are negative for both hbsag and hbeag inclusion criteria: * full-term neonates with gestational age from 37 weeks to 42 weeks; * apgar scores are no less than 7 at birth; * neonates with standard body temperature (auxiliary temperature \< 37.1°); * neonates weighing ≥ 2,500 grams at birth; * neonates with icteric index within the normal range (physiologic jaundice is permitted); * informed consent form signed by parent/guardian; * the requirements of the clinical trial protocol can be observed on the basis of the opinion of the investigator. exclusion criteria: * subject's parent has a history of family diseases such as convulsion and brain diseases; * mothers have low immunologic function or a history of organ transplantation or hemodialysis; * subject's parent is allergic to any composition of hepatitis b vaccine; * a family history of thrombocytopenia, or other disturbance of blood coagulation, which may result in a contraindication for intramuscular injection; * known immunologic function damage; * mothers had received gamma globulin or immunoglobulin injection during pregnancy; * any congenital malformation * known or suspected to suffer from diseases such as active infection and cardiovascular disease; * any condition believed by the investigator to have possible impact on trial evaluation.

Keywords: hepatitis b vaccine hepatitis b virus antigen antibody vaccination
umbilical cord derived mesenchymal stem cells therapy in parkinson's disease

Conditions: Parkinson's Disease

Summary: this study is to evaluate the safety and efficacy of umbilical cord derived mesenchymal stem cells transplantation in parkinson's disease.

parkinson's disease (pd) is a neurodegenerative movement disorder，which mainly shows up in the elderly. and there is as yet no effective drug treatment. umbilical cord derived mesenchymal stem cells (uc-mscs) derived from mesoderm owns strong proliferation ability and multiple differentiation potential. the investigators used uc-mscs via intravenous infusion to treat pd. with different durations of follow-up, the investigators cleared therapeutic effect, the quality of life and prognostic implications of uc-mscs on pd through the unified parkinson's disease rating scale (updrs), revised hoehn-yahr（h-y） staging, mini-mental state examination (mmse), hamilton depression scales 24 (hamd 24), hamilton anxiety scale 14 (hama 14) and clinical global impression (cgi). in this research, the investigators seek new therapeutic approaches for pd, and provide clinical evidences for the clinical application of uc-mscs in the future.

Eligibility criteria:
inclusion criteria: 1. age from 40 to 60 years, and no limitation of gender. 2. diagnosis of primary parkinson's disease(pd) according to movement disorder society (mds)-pd criteria established in 2015. 3. hoehn-yahr stages from i to iv stage. 4. drugs for anti parkinson's disease have been taken over 28 days before entering the group. 5. mmse score≥25 6. no antidepressant or antipsychotic drugs were received within 2 weeks. 7. understanding and willingness to sign a written informed consent document. exclusion criteria: patients with pd have to be disqualified from this study if any of the following is applicable. 1. patients with psychiatric history, but depression. 2. suicidal tendency or behavior of patients. 3. patients with severe cognitive impairment, chronic organ failure or malignant tumor. 4. the value of alanine aminotransferase (alt) and aspartate aminotransferase (ast) was 1.5 times higher than that of the normal reference; or leucocyte count\<1000/μl. 5. pregnancy and lactating women. 6. the patient is taking part in other drug tests, or received other research medication within 90 days before entering the group. 7. patients who had quit our study could not enter it again.
the early diagnosis of gestational diabetes mellitus study

Conditions: Gestational Diabetes Mellitus

Summary: the main purpose of the study is to evaluate an ogtt at 18 to 20 gestational weeks as an early diagnosis method of gdm in low risk pregnant women. by investigating maternal and neonatal outcomes that are associated with the early ogtt and regular ogtt results, the study will provide a evidence for the most appropriate time to perform an ogtt in pregnant women.


Eligibility criteria:
inclusion criteria: * singleton pregnant women will be invited to participate in this study if they are between 18 and 40 years of age, and have had their first prenatal visit in our center before 18 weeks 0 days of gestation. exclusion criteria: * previous history of gdm or preexisting dm * family history of diabetes mellitus (first degree relative with diabetes or a sister with gdm) * body mass index\>30 kg/m2 * previous macrosomia (baby with birth weight \>4,000 g) or a history of stillbirth * polycystic ovary syndrome * medications: corticosteroids, antipsychotics * participant not willing to take ogtt twice (at 18-20 gestational weeks and 24-28 gestational weeks), or not willing to have a series of prenatal care visits and deliver in our center.

Keywords: gestational diabetes mellitus oral glucose tolerance test
clinical characteristics and genetic profiles of severe combined immunodeficiency in china

Conditions: Severe Combined Immunodeficiency

Summary: severe combined immunodeficiency (scid), a rare primary immunodeficiency dieases (pid), is poorly characterized in mainland china. we meant to explore the patients with scid refered to our hospital and summarize their clinical manifestations and genetic features.

diagnostic criteria were based on recommendations by the pan-american group for immunodeficiency and the european society for immunodeficiencies, which included failure to thrive, persistent diarrhea, respiratory symptoms, and oral candidiasis, or pneumocystis pneumonia, severe bacterial infections, and disseminated bacillus calmette-guérin (bcg) infection during the first 2 to 7 months of life. in addition, patients included in the study were \<2 years of age, with either transplacentally acquired maternal t cells or \<20 % cd3+ t cells, the absolute lymphocyte count (alc) \<3000/mm3. exclusion criteria include hiv infection, congenital rubella, digeorge syndrome, zap70 deficiency, cartilage hair hypoplasia, pnp deficiency and mhc class ii deficiency.

Eligibility criteria:
inclusion criteria: diagnostic criteria were based on recommendations by the pan-american group for immunodeficiency and the european society for immunodeficiencies, which included failure to thrive, persistent diarrhea, respiratory symptoms, and oral candidiasis, or pneumocystis pneumonia, severe bacterial infections, and disseminated bacillus calmette-guérin (bcg) infection during the first 2 to 7 months of life. exclusion criteria: hiv infection, congenital rubella, digeorge syndrome, zap70 deficiency, cartilage hair hypoplasia, pnp deficiency and mhc class ii deficiency.

Keywords: clinical characteristics genetic profiles
the effect of gabapentin on thoracic epidural analgesia following thoracotomy

Conditions: Pain, Postoperative

Summary: the purpose of this trial is to investigate the effect of gabapentin on thoracic epidural analgesia following thoracotomy, including assessment of both analgesia, pain intensity, pain quality and whether or not gabapentin prevents the development of chronic pain conditions following thoracotomy. the main hypothesis is that gabapentin reduces the proportion of patients who develop a persistent pain condition following thoracotomy from 50% to 20%. furthermore gabapentin is expected to reduce both pain intensity measured on a 11-point numerical rating scale, usage of epidural infusions of local and/or opioid analgesics, morbidity, hospital length of stay, consumption of opioid analgesics and analgesia-related side-effects. in addition gabapentin is expected to improve postoperative recovery by means of postoperative lung function, walking ability, health related quality of life and patient satisfaction


Eligibility criteria:
inclusion criteria: * elective lung resection via thoracotomy * age \> 18 and \< 80 years exclusion criteria: * inability to answer the detailed questionnaires on pain and quality of life * psychiatric disease (icd-10) * severe renal impairment (se-creatinin \> 110 mmol/l) * known allergy to gabapentin, morphine, bupivacaine and / or ibuprofen * standard use of opioid analgesics * treatment with anticonvulsants or tricyclic antidepressants * use of antacids 24 hours before the intake of study medication * contraindicated placement of a thoracic epidural catheter * previous ipsilateral thoracotomy * presence of a chronic pain syndrome * acute pancreatitis * a history of past or current alcohol and / or illegal substance abuse. * a history of gastric or duodenal ulcer * gastrointestinal obstruction * pregnancy * participation in another intervention study

Keywords: gabapentin thoracotomy pain, postoperative analgesia recovery of function quality of life
v-y flap versus occlusive dressing in treating fingertip injuries with exposed bone

Conditions: Injury Arm

Summary: fingertip is a complex structure that is responsible for the fine function of the fingers and the whole hand. a fingertip injury is any soft tissue, nail or bony injury distal to the insertions of the long flexor and extensor tendons of a finger .fingertip injury is a serious condition that if untreated properly could lead to significant functional disability and disuse of the injured finger. up to date, defining the best treatment option for this injury remains controversial. hand surgeons are divided between proponents of flap coverage and conservative treatment, driven by beliefs, training programs and financial aspects. after recently reviewing the literature for the current best evidence and fundamentals of conservative treatment, krauss and lalandei in their recent review of the literature, pointed out to the necessity for implementing controlled trials to compare both ways of treatment.

the purpose of this study is to determine the efficacy and the results of occlusive dressing in treating fingertip injuries in comparison to flaps with much concern to certain factors that are closely related to our locality including patient compliance for regular follow up , functional outcome , time to return to work and its socioeconomical impact and cosmetic results . surgical group will undergo surgical coverage of the fingertip defect by v-y flap using the skin on the volar aspect of the same finger designed as v shaped then mobilized dorsally to cover the defect and stitches to be y shaped. stitches are removed after 2 weeks. conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks

Eligibility criteria:
inclusion criteria: * a. inclusion criteria: 1. age adults 12 - 60 years 2. diagnosis of fingertip injury with exposed bone (allen type 2, 3 or 4) in any finger. 3. informed consent obtained by the patient. exclusion criteria: * · old or complicated fingertip injuries. * non-exposed bone fingertip injury (allen type1). * patients with severe debilitating disease.

Keywords: occlusive dressing
long-term effect of 10 mg versus 20 mg rimonabant in overweight or obese patients

Conditions: Obesity; Weight Loss

Summary: the primary objective of this study is to assess, over a period of 12 months, the effect on weight loss and weight maintenance of rimonabant 10 mg in comparison with rimonabant 20 mg in overweight/obese patients after an initial treatment period of 6 months with rimonabant 20 mg. secondary objectives are to assess the effect of rimonabant over a period of 12 months on waist circumference, high-density lipoprotein (hdl)-cholesterol and triglycerides (tg), fasting plasma glucose (fpg), fasting insulin and to evaluate the long-term safety and tolerability of rimonabant 10 mg and 20 mg over a period of 12 months after randomization in overweight/obese patients.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) of at least 30 kg/m² or bmi \>27 kg/m² with associated risk factors such as type 2 diabetes or dyslipidemia exclusion criteria: * weight loss \> 5 kg within 3 months prior to screening visit. * presence of any clinically significant endocrine disease including the presence of type 1 diabetes * presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation including uncontrolled serious psychiatric illness such a major depression within the last 2 years, and history of other severe psychiatric disorders * previous participation in a clinical study with rimonabant * administration of other investigational drugs, anti-obesity drugs or other drugs for weight reduction * pregnancy and absence of effective contraceptive method for females of childbearing potential * exenatide * insulin therapy * recent change or need for change in the oral antidiabetic treatment * recent change or need for change in the lipid lowering treatment * presence of severe renal or hepatic impairment the above information is not intented to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: cholesterol hdl triglycerides insulin blood glucose
folfox/folfiri containing levofolinic acid (zuoyu ®) in the treatment of unresectable or metastatic colorectal cancer

Conditions: Unresectable or Metastatic Colorectal Cancer

Summary: to observe and evaluate the efficacy and safety of folfox/folfiri± target-directed regimen containing levofolinic acid (zuoyu ®) in first-line treatment of unresectable or metastatic colorectal cancer


Eligibility criteria:
inclusion criteria: * male or female, ≥18 years old; * patients with histopathologically confirmed unresectable or metastatic colorectal cancer who have not previously received chemotherapy or targeted therapy for unresectable or metastatic lesions; * have at least one measurable lesion according to recist 1.1 standards; * ecog ps score: 0-2; * expected survival greater than 3 months; * routine blood routine, liver and kidney function, electrocardiogram and other routine tests were basically normal, no contraindications of chemotherapy; * the subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up visits; * researchers believe treatment can benefit. exclusion criteria: * a proven allergy to the test drug and/or its excipients; * pregnant or lactating women; * patients judged by the investigator to be unsuitable for inclusion in this study;
obstructive sleep apnea and venous thromboembolism

Conditions: Obstructive Sleep Apnea; Venous Thrombosis; Pulmonary Embolism; Venous Thromboembolism

Summary: there is a clear link between obstructive sleep apnea (osa) and cardiovascular disease. however, there has been no clear link between osa and venous thromboembolism (vte). the objective of this study is to evaluate such a link.

design: 1. retrospective chart review of all patients with vte over 10 year period 2. retrospective chart review of all patients with osa over 10 year period 3. prospective 1 year follow up of all patients diagnosed with new vte 4. prospective 1 year follow up of all patients undergoing sleep study

Eligibility criteria:
inclusion criteria: * adult patients (\>= 18 years) with sleep study, osa or vte exclusion criteria: * below 18 years of age

Keywords: obstructive sleep apnea venous thrombosis pulmonary embolism venous thromboembolism
ultrasound elastography of salivary glands

Conditions: sjögren Disease

Summary: ultrasonography in salivary gland has demonstrated its usefulness to diagnose and follow patients with sjögren syndrome (pss). more recently, a new imaging technique allows to study the parenchymal elasticity in salivary glands and could be a new tool to evaluate patients with sicca syndrome and pss.


Eligibility criteria:
inclusion criteria: * male or female * more than 18 years old * consulting in doppler unit for sicca syndrome or suspicion of sjögren syndrome * consent agreement exclusion criteria: * no consent agreement * no sicca symptoms

Keywords: salivary glands ultrasonography elastometry elastography
hepatitis b vaccine predialysis/dialysis study (v232-060)

Conditions: Hepatitis B Virus Infection

Summary: to describe the immunogenicity and safety of modified process hepatitis b vaccine administered to renal predialysis and dialysis patients


Eligibility criteria:
inclusion criteria: * male and female subjects at least 18 years of age * laboratory confirmed negative serology result to hbsag (hepatitis b virus), anti-hbs (antibody to hepatitis b surface antigen), and anti hbc (antibody to hepatitis b core antigen) within 6 weeks of the initial dose of study vaccine * patient on renal dialysis or a pre-dialysis patient with a creatinine clearance of \<=30 ml/min exclusion criteria: * previous hepatitis b infection, vaccination with any hepatitis b vaccine * recent febrile illness; hypersensitivity to any component of licensed hepatitis b vaccines * recent administration of immune globulin, licensed inactivated vaccine within 14 days or licensed live vaccine within 30 days prior to receipt of first study vaccine * receipt of investigational drugs or investigational vaccines within 3 months prior * impairment of immunologic function * recent use of systemic immunomodulatory medications * pregnant women, nursing mothers or women planning to become pregnant

Keywords: hepatitis b virus